XENE Xenon Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1582313 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-100.0%
TTM net income YoY-40.0%
TTM EPS YoY-20.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-50.3%
ROA-47.4%
ROIC (approx.)-48.4%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets4.5%
Debt / equity0.00x
Current ratio21.19x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $7.50M | $0 |
| R&D expense | $95.64M | $99.22M | $88.51M | $87.70M | $77.05M | $74.98M | $61.20M | $59.47M |
| SG&A expense | $24.42M | $23.93M | $23.82M | $22.07M | $19.28M | $19.24M | $19.04M | $18.00M |
| Operating income | -$120.07M | -$123.16M | -$112.33M | -$109.77M | -$96.34M | -$94.23M | -$72.74M | -$77.48M |
| Pretax income | -$108.59M | -$111.32M | -$104.87M | -$104.72M | -$90.22M | -$85.33M | -$64.62M | -$69.53M |
| Income tax | $1.84M | -$585,000 | -$2.57M | $538,000 | $677,000 | -$626,000 | $427,000 | -$3.85M |
| Net income | -$110.44M | -$110.74M | -$102.30M | -$105.26M | -$90.90M | -$84.71M | -$65.05M | -$65.69M |
| EBITDA | -$119.50M | -$122.60M | -$111.74M | -$109.16M | -$95.69M | -$93.60M | -$72.08M | -$76.84M |
| EPS (basic) | -1.11 | -1.11 | -1.17 | — | -1.15 | -1.07 | -0.83 | — |
| EPS (diluted) | -1.11 | -1.11 | -1.17 | — | -1.15 | -1.07 | -0.83 | — |
| Weighted avg. shares (diluted) | 99.77M | 99.61M | 87.35M | — | 79.25M | 78.95M | 78.69M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $82.56M | $119.53M | $545.87M | $199.16M | $104.51M | $135.38M | $116.66M | $142.71M |
| Short-term investments | $868.24M | $811.16M | $548.88M | $349.72M | $357.75M | $352.16M | $432.97M | $484.19M |
| Receivables | — | — | — | — | — | — | — | $1.47M |
| Current assets | $960.07M | $945.87M | $1.11B | $560.65M | $480.14M | $500.25M | $565.54M | $635.26M |
| PP&E, net | $7.46M | $7.77M | $8.29M | $8.72M | $8.89M | $9.21M | $9.70M | $10.28M |
| Total assets | $1.20B | $1.30B | $1.39B | $633.16M | $607.84M | $674.28M | $743.28M | $798.14M |
| Current liabilities | $45.30M | $45.01M | $39.81M | $41.79M | $38.34M | $33.05M | $32.03M | $35.59M |
| Total liabilities | $53.49M | $53.38M | $48.99M | $51.40M | $48.33M | $40.30M | $39.32M | $43.24M |
| Shareholders' equity | $1.15B | $1.24B | $1.34B | $581.76M | $559.51M | $633.98M | $703.96M | $754.90M |
| Shares outstanding | 98.28M | 96.75M | 96.62M | 80.01M | 77.12M | 76.94M | 76.59M | 76.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$90.33M | -$95.39M | -$88.90M | -$81.48M | -$71.75M | -$64.23M | -$61.65M | -$54.38M |
| Capital expenditure | $284,000 | $275,000 | $133,000 | $318,000 | $281,000 | $157,000 | $43,000 | $783,000 |
| Free cash flow | -$90.61M | -$95.67M | -$89.03M | -$81.80M | -$72.03M | -$64.39M | -$61.70M | -$55.17M |
| Investing cash flow | $53.19M | -$331.24M | -$407.28M | $62.70M | $38.53M | $82.26M | $34.51M | $98.50M |
| Financing cash flow | $228,000 | $26,000 | $843.01M | $113.54M | $2.36M | $65,000 | $1.15M | $12.13M |
| Depreciation & amortization | $562,000 | $558,000 | $587,000 | $611,000 | $641,000 | $632,000 | $659,000 | $633,000 |
| Stock-based compensation | $16.55M | $16.73M | $16.89M | $14.12M | $13.71M | $13.71M | $12.17M | $13.60M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.